Eculizumab Biosimilar Comparable for Complement-Inhibitor Na

These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.

Related Keywords

Seoul , Soult Ukpyolsi , South Korea , Eculizumab Biosimilar , Oncology At Samsung Medical Center , Department Of Internal Medicine Division Hematology , Jun Ho Jang , Internal Medicine Division , Samsung Medical Center , Soo Min Lim , Non Asian Patients , Paroxysmal Nocturnal Hemoglobinuria , Subgroup Analysis , Global Phase , Controlled Trial , Eculizumab , Biosimilar , Sb12 ,